Waterloo Capital L.P. Increases Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Waterloo Capital L.P. lifted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 116.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,838 shares of the medical equipment provider’s stock after purchasing an additional 2,063 shares during the quarter. Waterloo Capital L.P.’s holdings in Intuitive Surgical were worth $1,707,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. Blair William & Co. IL grew its holdings in Intuitive Surgical by 5.3% during the second quarter. Blair William & Co. IL now owns 472,242 shares of the medical equipment provider’s stock valued at $210,077,000 after purchasing an additional 23,667 shares during the period. Zega Financial LLC lifted its position in shares of Intuitive Surgical by 18.9% in the second quarter. Zega Financial LLC now owns 2,184 shares of the medical equipment provider’s stock worth $972,000 after buying an additional 347 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in shares of Intuitive Surgical by 17.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 38,475 shares of the medical equipment provider’s stock worth $17,113,000 after buying an additional 5,726 shares in the last quarter. Tredje AP fonden lifted its position in shares of Intuitive Surgical by 34.9% in the second quarter. Tredje AP fonden now owns 23,176 shares of the medical equipment provider’s stock worth $10,310,000 after buying an additional 6,000 shares in the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. raised its position in Intuitive Surgical by 5.0% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 18,537 shares of the medical equipment provider’s stock valued at $8,246,000 after purchasing an additional 884 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Activity

In related news, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Desantis sold 376 shares of the stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $446.60, for a total transaction of $167,921.60. Following the completion of the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,458,979.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is currently owned by corporate insiders.

Intuitive Surgical Stock Performance

ISRG stock opened at $483.32 on Wednesday. The stock has a market capitalization of $171.43 billion, a P/E ratio of 87.24, a PEG ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $496.18. The company has a 50 day moving average price of $465.50 and a two-hundred day moving average price of $423.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the previous year, the business posted $1.18 EPS. The business’s quarterly revenue was up 14.5% on a year-over-year basis. Research analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

ISRG has been the topic of several recent analyst reports. The Goldman Sachs Group initiated coverage on Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target on the stock. Piper Sandler increased their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Barclays increased their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. BTIG Research increased their target price on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Finally, Truist Financial boosted their target price on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $446.45.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.